Getting an accurate diagnosis of solitary fibrous tumour involves several different tests and examinations that help doctors understand what type of growth you have and where it is located. Since these tumours often grow slowly and without symptoms for a long time, knowing when to seek medical attention and understanding the diagnostic process can make a significant difference in your care journey.

Who Should Undergo Diagnostics and When

Solitary fibrous tumours present a unique challenge because they often develop without causing any noticeable problems for extended periods. In fact, up to half of people with these tumours experience no symptoms at all until the growth becomes large enough to press against nearby organs, bones, or other tissues. This means that sometimes these tumours are discovered by accident during medical imaging done for completely different reasons.^[1][2]

You should consider seeking medical evaluation if you notice a lump or swelling in your soft tissues that doesn’t go away. While solitary fibrous tumours are often painless and slow-growing, any persistent growth deserves attention from a healthcare professional. The location of symptoms matters greatly because these tumours can form almost anywhere in the body, though they most commonly develop in the lining around the lungs called the pleura, which is the protective tissue that covers your lungs and lines your chest wall.^[1]

People who develop tumours in or around their lungs might experience chest pain, a persistent cough, coughing up blood, or shortness of breath. If a tumour forms in the abdomen, you might notice a swollen belly, difficulty fully emptying your bladder when urinating, constipation, or feeling uncomfortably full after eating only small amounts of food. Tumours in the head and neck region can cause blocked nose, voice changes, or nosebleeds. If a tumour develops in the area around your eyes, it might cause bulging eyes, double vision, drooping eyelids, eye pain, vision problems, or swollen, watery eyes.^[1][2][4]

Solitary fibrous tumours most commonly affect older adults, particularly people between the ages of 50 and 70, though they can occur at any age. They affect both males and females equally. These tumours are uncommon in children. The median age at diagnosis is around 65 years old. Anyone who experiences persistent symptoms in any part of their body, especially if they fall into the typical age range, should consult with a healthcare provider for proper evaluation.^[2][4]

Classic Diagnostic Methods

Diagnosing solitary fibrous tumour requires a multidisciplinary approach that combines several different types of examinations and tests. This comprehensive evaluation helps doctors not only confirm that you have a solitary fibrous tumour but also distinguish it from other types of soft tissue growths that might look similar. The diagnostic process typically begins with simpler examinations and progresses to more detailed testing as needed.^[3]

Physical Examination

The first step in diagnosis is usually a thorough physical examination. Your doctor will look at and carefully feel any lump or area of concern. This hands-on assessment helps determine the size, texture, and location of the growth, and whether it causes pain when touched. The physical examination also helps your doctor understand which additional tests might be most helpful in your specific situation.^[4]

Imaging Studies

Medical imaging plays a crucial role in evaluating solitary fibrous tumours because it allows doctors to see inside your body without surgery. Several different types of scans might be used, depending on where the tumour is located and what information your doctor needs.

Computed tomography (CT) scans use specialized X-ray equipment to create detailed cross-sectional images of your body. These scans are particularly useful for examining tumours in the chest, abdomen, and other areas. CT scans can show the size of the tumour, its exact location, and its relationship to nearby structures. At imaging, solitary fibrous tumours typically appear as well-defined masses. After contrast material is injected into a vein, these tumours usually show strong, uneven enhancement, which means they light up on the scan because they have a rich blood supply. Multiple blood vessels can often be seen at the edges of the tumour.^[7]

Magnetic resonance imaging (MRI) scans use powerful magnets and radio waves to create detailed pictures of soft tissues in your body. MRI is especially valuable for examining solitary fibrous tumours because it can reveal specific features that suggest this type of growth. A frequent characteristic of these tumours on MRI is the presence of rounded or linear areas that appear dark on both T1-weighted and T2-weighted images. These dark spots correspond to the fibrous and collagen-containing tissue within the tumour, which is a hallmark feature of solitary fibrous tumours.^[7]

Ultrasound uses sound waves to create real-time images of the inside of your body. Depending on where your tumour is located, different types of ultrasound might be used. For example, breast ultrasound, pelvic ultrasound, or specialized ultrasound of other body regions can help visualize the tumour and guide further testing.^[4]

While imaging studies provide valuable information about the size, location, and characteristics of a tumour, it’s important to understand that the imaging features of solitary fibrous tumours often overlap with those of many other benign and malignant tumours. This means that imaging alone usually cannot provide a definitive diagnosis. However, certain imaging features can raise suspicion for a solitary fibrous tumour and help guide the next steps in diagnosis.^[7]

Biopsy and Tissue Analysis

Because imaging findings are generally nonspecific, a biopsy is required for the final, definitive diagnosis of solitary fibrous tumour. A biopsy involves taking a sample of the tumour tissue so it can be examined under a microscope. This is the most important diagnostic test because it allows pathologists to see the actual cells and tissue structure of the tumour.^[4][7]

During a biopsy, your doctor will look to see if the tissue sample has the characteristic appearance of a solitary fibrous tumour. Under the microscope, these tumours show specific patterns that help distinguish them from other types of soft tissue growths. The pathologist will also perform additional specialized tests on the biopsy sample to confirm the diagnosis.^[4]

Immunohistochemical Testing

Immunohistochemistry is a laboratory technique that uses antibodies to detect specific proteins in tissue samples. For solitary fibrous tumours, one of the most important markers is STAT6. The presence of STAT6 protein in the nucleus of tumour cells is a highly reliable indicator of solitary fibrous tumour. In fact, STAT6 immunohistochemistry has emerged as a specific tool for diagnosing these tumours because it is positive in the vast majority of cases.^[3][5]

The reason STAT6 is such a useful marker relates to the underlying genetic changes in solitary fibrous tumours. Research has shown that these tumours typically have a specific genetic abnormality where two genes, called NAB2 and STAT6, fuse together. This creates what scientists call the NAB2-STAT6 fusion gene, and this genetic change is considered a hallmark of solitary fibrous tumours.^[2][3][5]

Molecular and Genetic Testing

In addition to immunohistochemical testing, molecular analyses can be performed to detect the NAB2-STAT6 fusion gene directly in the tumour tissue. This genetic testing provides another layer of diagnostic certainty. Scientists think that solitary fibrous tumour occurs when chromosomes in cells break and rejoin in the wrong way, leading to the fusion of these two genes. While researchers are still working to understand exactly why this happens and whether it directly causes the tumour to form, identifying this genetic change has become an important part of modern diagnosis.^[4][5]

Risk Stratification

Once a solitary fibrous tumour is confirmed, healthcare professionals assign it to a risk category. This risk assessment helps predict how likely the tumour is to come back after treatment or spread to other parts of the body. Solitary fibrous tumours can be classified as low risk, intermediate risk, or high risk. This categorization is based on several factors including your age, the size of the tumour, and what the tumour looks like under the microscope. Understanding the risk category helps your medical team plan appropriate treatment and follow-up care.^[1]

Although most solitary fibrous tumours are noncancerous and grow slowly without spreading, a subset of these tumours can demonstrate more aggressive behavior. The risk for spread to other parts of the body (metastasis) can be as high as 35 to 45 percent, or even greater in some studies with longer follow-up periods. This underscores the importance of accurate risk assessment and ongoing monitoring even after successful treatment.^[5]

Diagnostics for Clinical Trial Qualification

When patients are being considered for enrollment in clinical trials studying new treatments for solitary fibrous tumour, additional diagnostic requirements typically apply. Clinical trials have specific entry criteria to ensure that the right patients receive experimental treatments and that the study results will be meaningful and interpretable. The diagnostic tests used for clinical trial qualification often overlap with standard diagnostic methods but may be more stringent or include additional assessments.

For clinical trial enrollment, confirmed histological diagnosis through biopsy is essential. The biopsy must definitively show that you have a solitary fibrous tumour rather than another type of soft tissue growth. Immunohistochemical confirmation of STAT6 expression is typically required, as this provides molecular evidence that the tumour has the characteristic genetic features of solitary fibrous tumour. Some trials may also require direct molecular testing to confirm the presence of the NAB2-STAT6 fusion gene.^[3][5]

Imaging studies are crucial for clinical trial participation because they establish baseline measurements of the tumour. Trials usually require recent CT scans or MRI scans performed within a specific timeframe before enrollment. These baseline images allow researchers to measure the tumour’s size accurately and track whether it grows, shrinks, or remains stable during the trial. The imaging also helps determine the extent of disease, including whether the tumour has spread to other locations in the body, which affects trial eligibility.^[3]

Risk stratification is often important for clinical trial enrollment. Some trials specifically target high-risk tumours that are more likely to come back or spread, while others may include patients across all risk categories. The risk assessment, which considers factors like your age, tumour size, tumour location, and microscopic appearance, helps match patients to appropriate trials. Healthcare professionals may use standardized risk models to ensure consistent classification across different medical centers participating in the trial.^[5]

For trials testing treatments for advanced or metastatic disease, additional imaging may be needed to document all sites where the tumour has spread. This might include whole-body imaging studies to create a complete map of disease locations. Blood tests may also be required to assess your overall health and organ function, ensuring you can safely tolerate the experimental treatment being studied in the trial.

Because solitary fibrous tumours are rare, with only about 38 cases diagnosed per year in England and an incidence of 1 to 2 per million people worldwide, clinical trials for these tumours are relatively uncommon. When trials are available, the thorough diagnostic workup required for enrollment helps ensure that study participants truly have solitary fibrous tumour and that researchers can accurately measure treatment effects.^[4][7]

The multidisciplinary approach to diagnosing solitary fibrous tumours extends into the clinical trial setting. A team of specialists including pathologists, radiologists, oncologists, and surgeons work together to review diagnostic materials and determine trial eligibility. This collaborative assessment helps optimize patient outcomes and ensures that clinical research advances our understanding of these rare tumours in the most effective way possible.^[3]